The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
For decades, the pharmaceutical industry was built around the blockbuster model, developing medicines with broad indications capable of generating billions in annual revenue. These therapies, often de...
Canada’s biopharma sector is entering a defining phase where scientific ambition is increasingly intersecting with economic reality. Breakthroughs in gene therapies, precision medicine, and AI driven ...
